Modeling the Costs of Radiotherapy in Europe

AuntMinnie | This question is not addressed in an article in press published 26 August in Radiotherapy and Oncology comparing the cost of radiotherapy at a Belgian hospital in
calendar years 2000 and 2009. However, the content of the article — a financial
cost model showing how expenses almost doubled during the course of a decade of
cancer treatment technology evolution — brings this issue to the front of a
reader’s mind.

In Belgium, the 88.8 million euro ($126 million U.S.) budget to provide
radiotherapy services in 2009 was twice the amount budgeted in 2000, an increase
explained in part by a 40% surge in the number of patients who needed treatment,
according to the article’s corresponding author Dr. Yolande Lievens, a radiation
oncologist at the University Hospitals Gasthuisberg in Leuven, Belgium.

And at University Hospitals Leuven specifically:

  • The cost of capital investments by the department of radiation oncology
    increased by 96% in 2009 compared with 2000.
  • Personnel costs in the radiotherapy department increased by 103%.
  • The cost of resources to provide electron-beam radiotherapy treatments
    (EBRT) increased by 89%, from an expenditure of 4.5 million euros ($6.4 million)
    in 2000 to 8.6 million euros ($12.2 million) in 2009.
  • The number of EBRT treatment-related activities also skyrocketed, more than
    doubling from a total of 2.7 million activities in 2000 to 5.5 million
    activities in 2009.

The cost allocation model

In 2000, the hospital developed a detailed cost model for its department of
radiation oncology. It was updated in 2009 to incorporate and capture new types
of costs incurred by new types of treatment, such as stereotactic body
radiotherapy (SBRT), volumetric arc radiotherapy, image-guided radiotherapy,
respiratory-gated radiotherapy (RGRT), and intensity-modulated radiotherapy
(IMRT).

The model is based on ABC costing methodology, which assumes that activities
consume resources to produce products. The model includes resource costs and
activities costs.

Resource cost categories include hospital overhead costs to support the
department; costs associated with the physical space and rooms of the radiation
oncology department; wages for clinical, administrative, and support staff;
costs of equipment acquisition and maintenance; and material costs (both
consumable products and reusable products, such as a stereotactic frame).

Activity costs are categorized as being treatment-related,
department-supported, and hospital-supported. Products are defined as the list
of irradiation treatments that the department offers to patients. All costs are
ultimately allocated to products.

The cost model verified what the authors presumed: Costs increase with
treatment complexity, and more quality assurance activities also are needed to
guarantee safety as complexity escalates. The authors cited the example of 3D
conformal radiation therapy (CRT), which resulted in cost increases of
approximately 30% for tangential breast and high-grade palliative treatments.
Because the number of fractions for a treatment directly impacted costs,
increased use of hypofractionated schedules would decrease costs of a particular
treatment, and helped offset other costs incurred by its increased treatment
complexity.

2000 vs. 2009

The authors used EBRT, a treatment that was performed throughout the decade,
to evaluate cost changes and trends. The most significant activity trend was
that the percentage of cost allocated to quality assurance increased by 13%,
from 10% in 2000 to 23% of the total in 2009. The percentage of cost of portal
imaging, which had just begun to be used in 2000, increased from 2% to 14% of
the total EBRT cost in 2009. However, overall treatment delivery costs, which
included these two categories, remained relatively stable, at 69% and 73% in
2000 and 2009, respectively.

The department became more efficient over the decade with respect to both
planning treatments for patients and daily radiotherapy treatment delivery.
These costs declined respectively from 31% to 27% and from 56% to 45% of the
total.

Resource costs allocated to EBRT also were very consistent during the decade.
All costs were adjusted to the value of the euro in 2009.

Cost
category
2009
(% of
total)
2000
(% of
total)
Percent of
actual cost increase between 2000 and 2009 expenses
Equipment 33% 32% 195.8%
Material 4% 2% 288%
Space 3% 5% 0%
Hospital overhead 9% 13% 134.4%
Wages 51% 48% 202.6%

 

“Whether governments remain able and willing to cover cost increases largely
depends on the economical and political climate, both determining the accepted
growth in healthcare budgets,” Lievens and colleagues noted. While they believed
the improved quality of current radiotherapy technology would ultimately improve
patient outcomes, increased investment in radiotherapy treatments required solid
evidence on the added medical effectiveness of new interventions combined with
accurate data on their extra cost, they added.

ESTRO’s HERO project

The European Society for Radiotherapy and Oncology (ESTRO) concurs. It has
initiated an ambitious Health Economics in Radiation Oncology (HERO) project to
develop a knowledge base and a model for health economic evaluation of radiation
oncology in Europe. The project will address the need for radiotherapy,
provision and accessibility of treatments, waiting lists, staffing, cost
accounting, and economic evaluation.

Headed by Lievens and Dr. Cai Grau, a radiation oncologist at the Aarhus
University Hospital in Denmark, an 11-member task force of experts from Europe
and Canada is in the process of conducting an evidence-based survey of the need
for radiotherapy in Europe based on cancer epidemiology within different
European countries. The aim is to assess the actual status of radiotherapy in
Europe through a Web-based information/documentation center that will include
the actual levels of radiation oncology infrastructure, equipment, and staffing
in different European countries. It will include data on the actual treatments
delivered on an annual basis per country.

The cost accounting software model in development will allow users to
calculate cost data at multiple levels: from the European and country level, to
a department level, to a product (specific irradiation treatment) level. It will
benchmark costs at various levels. Its users will be able to evaluate
productivity at the national and department level and estimate the budgetary
impact of evolutions in technology. The model will also have the ability to
perform sensitivity analyses, such as the costs in cases of evidence-based
versus actual radiation oncology practices.

Economic models will also be developed to compute value for the cost of
radiotherapy treatments. Users of these models will be able to evaluate and
compare the cost-effectiveness and cost-utility of different radiotherapy
treatments and techniques, as well as compare radiotherapy treatments with other
oncology treatments that could be substituted. Users will be able to analyze
various cost expenditures to treat a cancer patient, and project them against
data relating to patient outcomes.

Ideally, the data generated by the HERO project will be able to be used for
key policymaking decisions. The HERO Task Force hopes to complete its project
and present its final results in 2013.

Read more on AuntMinnie.com.



Kyle Henneberry, M.D.

Associate Chief Medical Officer
Dr. Kyle Henneberry is a radiologist, health-tech innovator and one of the founders and principals of Direct Radiology. A native of Spokane, Washington, he graduated with honors in Biomedical Engineering from Northwestern University, received his medical degree from Case Western Reserve University in Cleveland, Ohio, and completed radiology residency at the University of Colorado. Dr. Henneberry has United States, Europe, Australia, and New Zealand.

Jerry Lee

Chief Technology Officer

Jerry Lee has over 25 years of experience in healthcare IT. and has been with ONRAD since 2013. As the CTO, he is responsible for developing the organization’s technology strategy including IT infrastructure, application development, data analytics, cybersecurity and overall risk management. Lee’s focus is on strategic road mapping, leveraging emerging technologies and business intelligence to automate, streamline and optimize business processes. He previously worked as a senior healthcare IT consultant, where he implemented best practices, policies & procedures, and risk mitigation strategies for a variety of clients. He also previously worked as the Business Intelligence and Analytics Project Manager for a leading healthcare SaaS organization. He graduated with a B.S. from the University of California, Irvine.

Leandra Hutchinson

President, Direct Radiology

Leandra Hutchinson joined ONRAD alongside the acquisition of Direct Radiology in December 2024. Hutchison has broad experience in the healthcare industry, spending her career in healthcare technology and innovation. Prior to joining Direct Radiology in 2019, Leandra was the co-founder and Vice President of Operations of a health-tech company specializing in radiology analytics and healthcare asset management. Previously, Leandra worked in marketing, strategy, and operations roles for more than 10 years at a $7B integrated delivery system of hospitals and medical centers with more than 900 employed physicians. Hutchison earned her Bachelor’s degree from Kent State University and graduate certificate in health care policy and administration and MBA from the University of Toledo.

Ron Jackson

President, AllRads

Ron Jackson serves as President of AllRads at ONRAD, bringing over 30 years of comprehensive healthcare leadership across the provider, payer, and technology landscape. With deep expertise in radiology, he has spent more than 25 years in revenue cycle management, operations, finance, and practice management roles at leading organizations including HBOC, Per-Se Technologies, McKesson, and Zotec Partners. At ONRAD, Jackson leads day-to-day operations and strategic execution of AllRads, drawing on his cross-functional experience to drive efficiency, scalability, and growth. His 360-degree perspective of the healthcare ecosystem uniquely positions him to align organizational strategy with market dynamics in teleradiology and imaging services.

Alix Vincent, M.D.

Chief Medical Officer

Dr. Alix Vincent was one of the founding physicians at ONRAD. With over 26 years of radiology leadership experience, Dr. Vincent oversees medical staff activities, including patient safety, quality, and risk management initiatives. He manages ONRAD’s Regional Medical Directors, evaluates staff physicians, and drives clinical improvements to enhance physician alignment within the organization. Additionally, Dr. Vincent leads medical operations and played a key role in developing the company’s PACS and RIS Network capabilities. He previously served as Chief Radiologist and Chairman of the Radiology Department at Riverside Regional Medical Center. Dr. Vincent holds an M.D. in Radiology from Loma Linda University.

Lyn Mize

Chief Financial Officer

Lyn Mize serves as Chief Financial Officer at ONRAD, a role she has held since June 2022. With over two decades of experience in financial leadership, Mize has held CFO positions at various healthcare organizations, including Sunset Media Entertainment and Oncology Convergence, Inc. She also served as Vice President of Accounting at Health Choice and System Director of Accounting at Scottsdale Healthcare. Mize has a strong background in financial management, having worked with Banner Health and Greeley Medical Clinic, where she provided financial leadership for multi-specialty clinics and physician networks. Mize holds extensive expertise in driving financial performance and strategic growth across the healthcare sector and has a B.S. from DeVry University and a Masters from Grand Canyon University.

Dave Engert

President & CEO

Dave Engert started at Onrad as President and CEO in 2017. Engert is a seasoned healthcare executive with over 35 years of experience and a proven track record of leading and transforming healthcare technology organizations to drive growth and improve operational and financial performance. He previously served as President and CEO of Nighthawk Radiology, the largest teleradiology provider, and led its successful sale to vRad. Engert also held the role of President and CEO of Quality Care Solutions (QCSI), a leading provider of health insurance software, which was sold to Trizetto. Additionally, he has held leadership roles at McKesson, HBOC, and other notable companies and invested in several healthcare technology ventures. Engert holds a B.S. in Industrial Engineering from Louisiana State University.